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events (VTE) in immobilized acutely ill general medical
inpatients from the hospital perspective in Germany.
METHODS: The incremental cost-effectiveness ratios
“additional cost for ENOX per clinical VTE averted
versus NPP” and “additional cost for ENOX per episode
of severe bleeding (ESB) averted versus UFH” were quan-
tiﬁed using a modelling approach based on decision-tree
technique. Resource use during thromboprophylaxis,
diagnosis, and treatment was collected from a hospital
survey. Costs were exclusively those to hospitals and were
determined by multiplying utilised resource items by the
price or tariff of each item. Clinical effectiveness was
taken from the MEDENOX [Samama et al. NEJM 1999]
and Thromboembolism-Prevention in Cardiac or Respi-
ratory Disease With Enoxaparin [Kleber et al. Am Heart
J 2003] trials and from a meta-analysis [Mismetti et al.
Thromb Haemost 2000]. The evaluation encompassed 8
(6–14) days of thromboprophylaxis plus time to treat
VTE and ESB in hospital. RESULTS: The base-case analy-
sis revealed incremental cost of €1543 for ENOX per clin-
ical VTE averted versus NPP, whereas ENOX dominated
UFH. In comprehensive sensitivity analyses, using impact
analysis and Monte Carlo simulation, the robustness of
the model was shown. In no case had the price of ENOX
the main impact on cost effectiveness. In 95% of 10,000
simulation steps, incremental cost for ENOX ranged
between €201 and 4 €154 per clinical VTE averted versus
NPP. In 91% of 10,000 simulation steps, ENOX
remained dominant over UFH. CONCLUSIONS: In
acutely ill general medical inpatients, ENOX offers 
hospitals in Germany a highly cost-effective thrombo-
prophylaxis compared to NPP and an enormous saving
potential when used instead of UFH.
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OBJECTIVES: Cardiovascular death is an important
endpoint in clinical trials. In health-economic analyses it
also plays a key role in the calculation of the number of
life years gained. Unlike other outcomes like myocardial
infarction (MI) or stroke, not much research has been
done on the assessment of speciﬁc resource use in patients
dying of a cardiovascular cause. This study assessed the
cost of cardiovascular death in Belgium. METHODS: In
this cost-of-illness study, data on resource utilisation were
retrospectively collected in patients with a history of MI
who died in the hospital in the year 2002. Four hospitals
were selected based on setting (community-university)
and geographical region (north and south). Direct
medical costs from the health care payer’s perspective, as
expressed by the intensity of medical resource consump-
tion in physical units, times the direct cost or charge per
unit, were considered. Costs were deﬁned as cost of hos-
pitalisation (basic care and nursing), drug use, diagnostic
tests, physician consults and technical interventions.
RESULTS: The charts of 60 patients were reviewed (mean
age: 76 ± 11 years). The average length of stay was 5.28
days (St. Err. 0.64). The main causes of death were MI
(37%), cardiogenic shock (22%) and ventricular ﬁbrilla-
tion (20%). The average hospitalisation cost €2045 (St.
Err. €215), the drug cost €383 (St. Err. €97), the cost of
diagnostic tests €344 (St. Err. €42), the cost of physician
consults €29 (St. Err. €7) and the cost of technical inter-
ventions €943 (St. Err. €207), resulting in a total cost 
of death from cardiovascular disease of €3744 (St. Err.
€431). In the Northern part the average cost is about
€1000 higher compared to the Southern part (€4284 vs.
€3239) (NS). CONCLUSIONS: Cardiovascular death 
is not only an important clinical endpoint but also an
important economic parameter due to its high cost.
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OBJECTIVE: Results from the Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE) study
showed that clopidogrel plus aspirin, comparing to
aspirin alone, reduced the cardiovascular events (death,
myocardial infarction, and stroke) in patients with acute
coronary syndromes (ACS). Yet the acquisition cost of
clopidogrel is much higher. It would therefore be worth-
while to compare the long term cost impact of these 2
regimens. METHODS: Until recently, only very few
patients with ACS received a clopidogrel-aspirin combi-
nation therapy in Hong Kong. Therefore a hypothetical
cohort was formed and compared to a real group of
patients treated with aspirin alone. For the aspirin group,
medical history was reviewed and cardiovascular and gas-
trointestinal events occurring in a period of 12 months
after initiation of therapy were recorded. The target cost
items included hospitalisation, emergency room visits,
outpatient clinic visits, related medications, diagnostic
tests, procedures and surgery. For the hypothetical
cohort, the probabilities/relative risks for clinical events
were adopted from the CURE study. The unit cost of
drugs and other resource items were based on the Hong
Kong Hospital Authority drug acquisition cost 2001 and
Hong Kong Government Gazette 2003 respectively. The
perspective of the study was that of a public health organ-
isation. RESULTS: Fifty-four consecutive patients with
ACS receiving aspirin therapy were identiﬁed over the
period of January 1, 2001 to December 31, 2001 from 
a major public hospital in Hong Kong and studied. 
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The average cost of management per patient over the 
10-month period of this group was HKD85,324
(USD$10,940, HKD7.8 = USD$1). Hospitalisation rep-
resented the major cost item (64.6%), followed by cost
of investigational tests (14.5%) and procedural cost
(11.6%). The average cost per patient in the hypothetical
cohort was HKD83,903 (USD$10,757). CONCLUSION:
According to our analytical model, the overall cost impact
between clopidogrel plus aspirin vs aspirin alone in the 2
groups of patients was similar.
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OBJECTIVES: The isosmolar contrast medium (CM)
iodixanol has been shown to reduce the risk of major
adverse cardiac events and have a higher intervention
success rate compared with the low-osmolar agent
ioxaglate in patients undergoing PCI at high risk of com-
plications. The purpose of this study was to assess to what
extent this clinical beneﬁt is associated with differences in
health care costs for PCI patients in France and Spain.
METHODS: A decision tree model was developed to
compare the costs associated with receiving each CM in
high-risk and low-risk patients. Clinical data were derived
from published comparative clinical trials. Data on
medical resource use associated with managing adverse
events were obtained from panels of French and Spanish
interventional cardiologists, and resource use was con-
verted to costs using nationally representative country-
speciﬁc tariffs. The study end-point was the difference
between CM groups in the cost of treatment during the
hospitalization period for a patient undergoing PCI. Uni-
variate sensitivity analyses were performed to test the
robustness of the results. RESULTS: In France, the direct
cost of treatment per high-risk patient for iodixanol was
€231 lower than for ioxaglate. The direct cost of treat-
ment per low-risk patient was €45 higher for iodixanol
than for ioxaglate. In Spain, the direct cost of treatment
for iodixanol compared with ioxaglate was €220 lower
per high-risk patient and correspondingly €92 higher per
low-risk patient. CONCLUSIONS: This study suggests
that in high-risk patients undergoing PCI, the use of
iodixanol confers an economic beneﬁt as well as a clini-
cal beneﬁt in each study country. For low-risk patients a
converse economic beneﬁt is seen. When considering all
patients these results suggest that the use of iodixanol
confers an economic beneﬁt if the proportion of high-risk
patients exceeds 30% in Spain and 17% in France.
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OBJECTIVES: To evaluate the inpatient and outpatient
maintenance costs associated with treatment for acute
myocardial infarction in the Greek NHS. METHODS: A
database from a large NHS University Hospital was
employed and analyzed. Resource consumption data were
combined with 2003 price data to compute overall treat-
ment costs. Inpatient costs of an uncomplicated AMI
comprise all costs associated with treating an event in-
hospital and these include the costs of wards, PTCAs,
medications, cardiac ICU, etc. The marginal costs of
having one of many types of events, such as strokes, re-
infarction, etc, are also computed. The outpatient main-
tenance costs of patients include medication taken after
the AMI for certain period or life-time, visits to profes-
sionals and rehabilitation in cases of events such as
strokes. RESULTS: The costs of initial inpatient medica-
tion given is between €790 and €1000. The average cost
of hospitalization is about €8.474 and the additional cost
per event is as follows: stroke—€1300, bleeding—€90,
reinfraction—€1125, recurrent ischemia: 0, CHF—€561,
hypotention: 0, cardiogenic chock—€1.730, electro-
mechanical dissociation—€121, tamponate or cardiac
rapture—€279, second degree atrioventicular block—
€961, third degree atrioventicular block: €1.521, artial
ﬁbrillation: €100, asystole: €121, acute mitral requirgita-
tion—€1.415, septal defect: €415, anaphylaxis:€300, 
pulmonary embolism: €2.050, arrythmias: €100, hypo-
tention: €0, pericarditis—€100. The cost of rehabilitation
and maintenance is on average €915 in the ﬁrst year plus
€4.5 per day after discharge and during lifetime thereafter.
Severe stroke is associated with an extra of €1.000 in the
ﬁrst year. CONCLUSION: AMI is an expensive to treat
event. The cost of initial medication given is low in com-
parison with the total treatment cost within the hospital
and after discharge. The associated events are also very
expensive to treat and multiply total cost. Any reduction
therefore in MI’s, given the high prevalence, will save the
NHS and the taxpayer a lot of money.
